Are There FDA-Approved Medications for POTS?
At a Glance
Currently, there are no FDA-approved medications specifically for Postural Orthostatic Tachycardia Syndrome (POTS). Instead, doctors prescribe off-label drugs like beta-blockers and fludrocortisone to manage symptoms, helping patients participate in long-term therapies like graded exercise.
Currently, there are no medications specifically approved by the Food and Drug Administration (FDA) to cure or treat Postural Orthostatic Tachycardia Syndrome (POTS) [1][2]. Because of this, clinical management relies on the “off-label” use of medications originally approved for other conditions, such as hypertension, heart failure, or neuromuscular disorders [3][4].
The Role of Medication: A “Pharmacological Bridge”
Instead of aiming for a direct cure, doctors prescribe medications in POTS to control specific, debilitating symptoms [5]. The goal is to create what specialists call a “pharmacological bridge.” By stabilizing your heart rate and blood pressure, these medications can reduce symptoms enough to allow you to actively participate in essential non-drug therapies [6][7].
Lifestyle modifications—such as structured, graded exercise programs, increased salt and fluid intake, and wearing compression garments—are considered highly effective strategies for managing POTS in the long term [6][8]. However, when symptoms are severe, it is often too difficult to start these therapies without the support of symptom-controlling medications.
Tip: Some patients find it helpful to take their morning medications before even sitting up in bed to help control symptoms right from the start of the day.
Common Off-Label Medications for POTS
Treatment is highly individualized and focuses on the specific underlying drivers of your POTS symptoms, such as low blood volume (hypovolemia) or high adrenaline levels (hyperadrenergic state) [5][9]. While high-quality randomized controlled trial data for many of these medications in POTS remain limited, available reports show favorable effects for many patients [2][10].
Commonly prescribed off-label medications include:
- Beta-blockers (e.g., Metoprolol, Propranolol): These medications help blunt the excessive heart rate response (tachycardia) upon standing [3][2]. Safety Note: Because they can also lower blood pressure and energy levels, they may temporarily cause increased fatigue or lightheadedness.
- Ivabradine: A medication that specifically lowers the heart rate without significantly dropping blood pressure. It has been shown to improve symptoms in some patients with POTS [11][4].
- Fludrocortisone: A synthetic steroid that helps your body retain sodium and fluids, addressing low blood volume (hypovolemia) [1][9]. Safety Note: This medication can cause your body to lose potassium (hypokalemia), so your doctor will likely monitor your blood levels regularly.
- Midodrine: A medication that constricts blood vessels to improve blood pressure and help pump blood back up to the heart [1][9]. Safety Note: Midodrine can cause dangerously high blood pressure if you lie flat (supine hypertension). You should avoid taking it within a few hours of bedtime or lying down flat while it is active.
- Central Sympatholytics (e.g., Clonidine, Guanfacine): Often used for patients with the hyperadrenergic subtype of POTS, these medications help calm the central nervous system and reduce adrenaline surges [2].
- Pyridostigmine (Mestinon): This medication enhances the signaling of the parasympathetic (“rest and digest”) nervous system [12]. It may help reduce overall symptom burden in POTS [13][14]. Safety Note: Common side effects can include stomach cramps and muscle twitching [15][16].
Your doctor may adjust your medications over time. Finding the right combination and dosage is often a process of trial and error tailored to your unique symptom profile [17][18].
Common questions in this guide
Are there any medications FDA-approved to cure POTS?
Why do doctors prescribe off-label drugs for POTS?
What are the most common medications used to treat POTS?
What are the safety risks of taking midodrine for POTS?
When is the best time to take my morning POTS medications?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Which specific POTS subtype or underlying driver (e.g., hypovolemic, hyperadrenergic) do you suspect I have?
- 2.What are the specific side effects or warning signs that should prompt me to call your office after starting this medication?
- 3.How long should we try this dosage before we decide whether it is working?
- 4.What should I do if this medication lowers my blood pressure too much or makes my fatigue worse?
- 5.Do you recommend I take my first dose of medication before sitting up in bed in the morning?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (18)
- 1
Postural orthostatic tachycardia syndrome: pathophysiology, management, and experimental therapies.
Narasimhan B, Aggarwal D, Satish P, et al.
Expert opinion on investigational drugs 2022; (31(10)):1017-1025 doi:10.1080/13543784.2022.2121697.
PMID: 36094001 - 2
Treatment of Postural Orthostatic Tachycardia Syndrome With Medication: A Systematic Review.
Hasan B, Almasri J, Marwa B, et al.
Journal of child neurology 2020; (35(14)):1004-1016 doi:10.1177/0883073820948679.
PMID: 32838632 - 3
Predicting Therapeutic Efficacy of Pharmacological Treatments in Children with Postural Orthostatic Tachycardia Syndrome: A Mini-Review.
Fan S, Cui Y, Liao Y, Jin H
Children (Basel, Switzerland) 2023; (10(7)) doi:10.3390/children10071093.
PMID: 37508589 - 4
Ivabradine in the treatment of postural tachycardia syndrome (POTS), a single center experience.
Ruzieh M, Sirianni N, Ammari Z, et al.
Pacing and clinical electrophysiology : PACE 2017; (40(11)):1242-1245 doi:10.1111/pace.13182.
PMID: 28846151 - 5
Orthostatic intolerance and postural tachycardia syndrome: new insights into pathophysiology and treatment.
Ruzieh M, Grubb BP
Herzschrittmachertherapie & Elektrophysiologie 2018; (29(2)):183-186 doi:10.1007/s00399-018-0563-1.
PMID: 29696346 - 6
The international POTS registry: Evaluating the efficacy of an exercise training intervention in a community setting.
George SA, Bivens TB, Howden EJ, et al.
Heart rhythm 2016; (13(4)):943-50.
PMID: 26690066 - 7
Infectious mononucleosis complicated by peritonsillar abscess and postural orthostatic tachycardia syndrome: A case report.
Yaxley KL
SAGE open medical case reports 2020; (8()):2050313X20915413 doi:10.1177/2050313X20915413.
PMID: 32284866 - 8
Message from the Guest Editors.
Rich E, Vas A
Occupational therapy in health care 2022; (36(3)):199-201 doi:10.1080/07380577.2022.2080417.
PMID: 35640031 - 9
Pathophysiological mechanisms of Postural Orthostatic Tachycardia Syndrome analyzed by means of hemodynamics.
Wei L, Cheng H, Chen S, et al.
PloS one 2025; (20(7)):e0327236 doi:10.1371/journal.pone.0327236.
PMID: 40601666 - 10
Noninvasive Vagal Nerve Stimulation for the Treatment of Postural Orthostatic Tachycardia Syndrome: A Comprehensive Review.
Tran HH, Thu A, Fuertes A, et al.
Cardiology in review 2025; doi:10.1097/CRD.0000000000000953.
PMID: 40401908 - 11
Ivabradine in children with postural orthostatic tachycardia syndrome: a retrospective study.
Towheed A, Nesheiwat Z, Mangi MA, et al.
Cardiology in the young 2020; (30(7)):975-979 doi:10.1017/S1047951120001341.
PMID: 32498748 - 12
Pyridostigmine improves hand grip strength in patients with myalgic encephalomyelitis/chronic fatigue syndrome.
Schlömer E, Stein E, Kedor C, et al.
Frontiers in neuroscience 2025; (19()):1637838 doi:10.3389/fnins.2025.1637838.
PMID: 40970182 - 13
Self-reported symptom burden in postural orthostatic tachycardia syndrome (POTS): A narrative review of observational and interventional studies.
Knoop I, Picariello F, Jenkinson E, et al.
Autonomic neuroscience : basic & clinical 2023; (244()):103052 doi:10.1016/j.autneu.2022.103052.
PMID: 36525900 - 14
The evidence for treatments for postural orthostatic tachycardia syndrome: a systematic review of randomized trials.
Kwok CS, Lee S, Hall M, et al.
Trends in cardiovascular medicine 2025; (35(8)):517-527 doi:10.1016/j.tcm.2025.07.001.
PMID: 40653179 - 15
The effectiveness and side effects of pyridostigmine in the treatment of myasthenia gravis: a cross-sectional study.
Remijn-Nelissen L, Verschuuren JJGM, Tannemaat MR
Neuromuscular disorders : NMD 2022; (32(10)):790-799 doi:10.1016/j.nmd.2022.09.002.
PMID: 36184373 - 16
Pyridostigmine for the treatment of gastrointestinal symptoms in systemic sclerosis.
Ahuja NK, Mische L, Clarke JO, et al.
Seminars in arthritis and rheumatism 2018; (48(1)):111-116 doi:10.1016/j.semarthrit.2017.12.007.
PMID: 29397195 - 17
The patient perspective: What postural orthostatic tachycardia syndrome patients want physicians to know.
Stiles LE, Cinnamon J, Balan I
Autonomic neuroscience : basic & clinical 2018; (215()):121-125 doi:10.1016/j.autneu.2018.06.002.
PMID: 29903594 - 18
Understanding postural orthostatic tachycardia syndrome.
Stuart C, Stuart R, Dunn H, et al.
British journal of nursing (Mark Allen Publishing) 2025; (34(5)):288-292 doi:10.12968/bjon.2024.0272.
PMID: 40063544
This page provides information about off-label medication use for POTS for educational purposes only. Always consult your doctor to find the safest and most effective treatment plan for your specific symptoms.
Get notified when new evidence is published on Postural Orthostatic Tachycardia Syndrome (POTS).
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.